BioAtla Investor Presentation Deck

Potential market opportunity in metastatic NSCLC ● >540K 2L+ people in the U.S. living with lung cancer¹ bicatla despite advances in 1L care, majority of patients progress³ ~200K ~75% newly diagnosed patients / year (U.S.) - majority advanced / metastatic² non-squamous cell represents majority of patients4 Available Treatment: 1L: Chemo + ICI 50% ORR5 2L+: SOC 10% - 20% ORR6,7 Target population: ~50K AXL+ addressable 2L+ patients/year in the U.S.8, based on AXL positivity rate of ~35% Internal success threshold: 2L+ ORR of ~15% - 20% (approvability bar); 20%+ (commercially relevant) following BA3011 monotherapy ¹https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet 2https://www.cancer.net/cancer-types/lung-cancer-non- small-cell/statistics, ³Wang F, Wang S and Zhou Q (2020) The Resistance Mechanisms of Lung Cancer Immunotherapy. Front. Oncol. 10:568059. doi: 10.3389/fonc.2020.568059, 4https://thoracickey.com/carcinomas-of-the-lung-classification-and-genetics/#F1-72 5Transl Lung Cancer Res 2021;10(7):3093-3105. Ann Oncol. 2017;28(11):2698-706. DOI: 10.1200/JCO.22.00912 Journal of Clinical Oncology Published online June 03, 2022. Clarivate, Disease Landscape and Forecast: NSCLC (2022). 1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate (best objective response as confirmed complete response or partial response), SOC, standard of care (docetaxel, docetaxel + ramucirumab, gemcitabine, pemetrexed) BioAtla| Overview 16

View entire presentation